The New 2016 IDSA HAP/VAP Guidelines – A Long Awaited Update

Dr. Curtis Harder, BSc(Pharm), PharmD, ACPR Clinical Pharmacy Specialist – Adult Intensive Care Coordinator, Pharmacy Education & Practice Residency, VIHA Clinical Assistant Professor, Faculty of Pharmaceutical Sciences, UBC

The 2016 IDSA HAP/VAP Guidelines were long awaited with 11 years passing since the publication of the previous version. This presentation will condense the salient points especially relevant to pharmacy practice to and highlight where controversy may exist.


Let’s Explore Dyslipidemia Guidelines, Etc.

Arden Barry, BSc, BSc(Pharm), PharmD, ACPR Clinical Pharmacy and Research Specialist, Lower Mainland Pharmacy Services; Assistant Professor (Partner), Faculty of Pharmaceutical Sciences, University of British Columbia; Associate Member, Department of Family Practice, Faculty of Medicine, University of British Columbia

The treatment of dyslipidemia is controversial despite a plethora of available published evidence. This has led to the development of multiple dyslipidemia guidelines— while these documents differ with respect philosophy and complexity, they are more similar than they are different. This presentation aims to explore three recently published dyslipidemia guidelines with the goal of deriving a few pragmatic considerations that participants can apply in practice.